FindTrial
Sign In

opaque

DRUG2 trials

Sponsors

Eip Pharma Inc., Region Uppsala

Conditions

2017)Major DepressionMajor Depression Disorder (MDD)Subjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by consensus criteria (McKeith et albut the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD)including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negativethis will also qualify as probable DLB.

Phase 2

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
CompletedCTIS2023-504373-20-00
Eip Pharma Inc.2017), but the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD), including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negative +2
Start: 2023-08-09End: 2025-05-12Target: 15Updated: 2025-03-25
AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial
RecruitingCTIS2025-521686-27-01
Region UppsalaMajor Depression, Major Depression Disorder (MDD)
Start: 2026-01-08Target: 105Updated: 2025-11-21